ACHV - Achieve Life Sciences Inc logo

Achieve Life Sciences Inc

ACHV

Achieve Life Sciences develops and commercializes cytisinicline, a treatment for nicotine dependence in North America and the UK. The drug targets nicotine receptors to alleviate withdrawal symptoms, aiming to help smokers quit effectively.

βš•οΈ Healthcare NASDAQ Listed 1995 $ USD
$1,000 invested 30 years ago β†’$0today

Score Overview

1 Year
Scoreβ€”
Net Growth-108.68%
Net TrendShrank
Net Income Consistencyβ€”
Rev Growthβ€”
Rev TrendShrank
Revenue Consistencyβ€”
5 Years
Scoreβ€”
Net Growth-246.61%
Net Trend20%
Net Income Consistencyβ€”
Rev Growthβ€”
Rev TrendNever
Revenue Consistencyβ€”
10 Years
Score
Net Growth-466.55%
Net Trend30%
Net Income Consistency
Rev Growth-100.00%
Rev TrendNever
Revenue Consistency
20 Years
Score1.5
Net Growth-384.22%
Net Trend40%
Net Income Consistency
Rev Growth-100.00%
Rev Trend20%
Revenue Consistency
30 Years
Score
Net Growth-67x
Net Trend37%
Net Income Consistency
Rev Growth-100.00%
Rev Trend30%
Revenue Consistency
All Time
Score
Net Growth-17x
Net Trend39%
Net Income Consistency
Rev Growth-100.00%
Rev Trend32%
Revenue Consistency

Explore the 2021 public Archive ranking β†’

Where Achieve Life Sciences Inc has ranked, year by year

Measure
Fundamentals Window

Showing 5 years ranking history by HDB Score.

Has not reached the top 50 on HDB Score in any year we have ranked.

  • ACHV

2001: 88.7% Β· 2021: 93.5% Β· free through 2021 Β· longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-30
$ 8.09β€”
1 Year2025-09-30
$ 3.15156.83%
5 Years2021-09-30
$ 8.50-4.82%
10 Years2016-09-30
$ 1.12K-99.27%
20 Years2006-09-29
$ 185.72K-100.00%
30 Years1996-09-27
$ 772.2K-100.00%
All Time1995-10-13
$ 282.15K-100.00%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 0.00-$ 114M$ 187M
2025$ 0.00-$ 54M$ 36M
2024$ 0.00-$ 39M$ 34M
2023$ 0.00-$ 29M$ 15M
2022$ 0.00-$ 41M$ 24M
2021$ 0.00-$ 32M$ 43M
2020$ 0.00-$ 14M$ 35M
2019$ 0.00-$ 16M$ 16M
2018$ 0.00-$ 12M$ 14M
2017$ 0.00-$ 10M$ 5M
2016$ 5M-$ 20M$ 25M
2015$ 18M-$ 16M$ 55M
2014$ 27M-$ 26M$ 47M
2013$ 29M-$ 31M$ 39M
2012$ 20M-$ 21M$ 75M
2011$ 5M-$ 14M$ 64M
2010$ 13M-$ 12M$ 85M
2009$ 25M$ 5M$ 64M
2008$ 20M-$ 4M$ 13M
2007$ 20M-$ 13M$ 34M
2006$ 22M-$ 23M$ 58M
2005$ 8M-$ 21M$ 49M
2004$ 264M-$ 16M$ 20M
2003-$ 10M$ 19M
2002-$ 11M$ 16M
2001$ 8M$ 542.18K$ 15M
2000$ 408.41K-$ 2M$ 13M
1999$ 12M$ 400K$ 16M
1998$ 5M-$ 11M$ 17M
1997$ 18M$ 1M$ 5M
1996$ 16M$ 1M$ 7M
IPO1995$ 4M-$ 5M$ 5M
ACHV - Achieve Life Sciences Inc logo

Achieve Life Sciences Inc fundamental performance

Between 2005 and 2025, revenue declined from $ 8M to $ 0.00 and net income went from -$ 21M to -$ 54M. Revenue increased in 4 of those 20 years; net income in 8.

Across Achieve Life Sciences Inc's full reported history, from 1995 to 2025, revenue declined from $ 4M to $ 0.00 and net income went from -$ 5M to -$ 54M. Revenue increased in 32% of the years measured; net income in 39%.

Achieve Life Sciences Inc currently holds a 20-year HDB Score of 1.5 out of 10. How the HDB Score is calculated.

Membership

Continue ACHV’s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,814 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year Β· Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies